Knowledge Area 14 | Gynaecological Oncology
(Aligned with RCOG Core Curriculum 2019)
Gynaecological Oncology is a high-yield module in MRCOG Part 2. Questions are inevitable. The key to scoring well is systematic preparation with emphasis on:
- Staging (FIGO)
- Referral pathways
- MDT management
- Evidence-based treatment protocols
- Genetics & survivorship
- Fertility preservation
- Palliative and end-of-life care
This module must be approached organ-wise but thought about systemically. Your notes are VITAL in this module
What the RCOG Curriculum Expects
According to the RCOG Core Curriculum, trainees must demonstrate competence in:
- Prevention and screening
- Diagnosis and staging (including imaging modalities)
- Interpretation of tumour markers
- Surgical principles
- Chemotherapy, radiotherapy & targeted therapies (basic understanding)
- Referral to specialist cancer centres
- Genetic counselling pathways
- Survivorship issues
- End-of-life care
There is now stronger emphasis on:
- Genomic medicine (BRCA, Lynch syndrome)
- Risk-reducing surgery
- Sentinel lymph node biopsy
- Enhanced recovery after surgery (ERAS)
- Centralisation of oncology care
- Shared decision-making
How to Organise Your Study
Create a master folder: Gynaecological Oncology
Subfolders:
- Cervix
- Endometrium
- Ovary & Fallopian Tube
- Vulva & Vagina
- Genetics & Risk Reduction
- General Oncology Principles
For each cancer, structure your notes under the same headings:
- Epidemiology & risk factors
- Pathogenesis (HPV, genetic mutations, etc.)
- Screening (if applicable)
- Clinical presentation
- Investigations & imaging
- FIGO staging (MUST revise repeatedly)
- Stage-wise management
- Fertility-sparing options
- Prognosis & survival
- Recurrence management
- MDT pathway
Consistency in structure improves retention and recall.
Cervical Cancer
- Core areas include: HPV pathogenesis; Cervical screening programme; Colposcopy principles; CIN management; Reproductive outcomes after LLETZ; Fertility-sparing surgery (trachelectomy); Stage-wise management; Chemoradiation principles
- Know the UK screening framework and HPV primary testing pathway (current national approach).
- Understand centralisation of care and referral to Gynae Oncology MDT.
Endometrial Cancer
- Increasingly common and heavily examined. Important updates include: Obesity as major risk factor; Role of Lynch syndrome testing; Molecular classification (TCGA-based understanding at basic level); Sentinel lymph node biopsy; Adjuvant therapy principles
- Green-top Guideline No. 67 (Endometrial Hyperplasia) remains essential.
- You must know: Management of postmenopausal bleeding; Atypical hyperplasia vs carcinoma; Surgical staging principles; Risk stratification
Ovarian & Fallopian Tube Cancer
- This area has seen significant evolution. You must understand: Risk of Malignancy Index (RMI); CA125 interpretation; NICE referral thresholds; Role of imaging; BRCA mutation testing; PARP inhibitors (basic principle only); Interval debulking vs primary cytoreduction; Borderline tumours; Germ cell tumours (younger women)
- Be aware that high-grade serous carcinomas are now understood to often originate from the distal fallopian tube.
- Risk-reducing salpingo-oophorectomy is an important exam topic.
Vulval & Vaginal Malignancy
- A few questions may come in the exam. You must know: VIN classification; Vulval dermatoses vs malignancy; Sentinel lymph node biopsy; Surgical margins; Management in elderly population; MDT care
Genetics & Risk Reduction (Increasingly Tested)
- Now there is more emphasis in the curriculum. You must understand: BRCA1/2 mutations; Lynch syndrome; Genetic counselling pathways; Risk-reducing surgery; HRT after RRSO; Fertility preservation options
- Genomics is no longer optional knowledge in MRCOG but a MUST.
Fertility-Sparing & Survivorship
- One of the important exam topics. You are expected to know: Trachelectomy; Fertility-sparing treatment in endometrial cancer; Oocyte/embryo preservation; Impact of radiotherapy; Sexual dysfunction after treatment; HRT following gynaecological cancer; Psychological support
General Oncology Principles (Do Not Neglect)
- You must have a basic understanding of: Radiotherapy mechanisms; Chemotherapy drugs and regimens; Targeted therapy principles; Immunotherapy basics; ERAS protocols; Management of bowel obstruction; Ascites management; Palliative care principles: Breaking bad news
- The curriculum now expects holistic oncological competence, not just tumour knowledge.
Main changes in new curriculum
- Greater emphasis on genomics and molecular classification
- Sentinel lymph node biopsy incorporated in staging
- More conservative/fertility-preserving approaches
- Increased focus on survivorship and quality of life
- Stronger governance and MDT centralisation
- Risk-reducing surgery and prophylaxis as examinable topics
For last-minute revision:
- Memorise FIGO staging tables
- Know referral thresholds
- Revise tumour markers
- Remember fertility-sparing indications
- Be confident in genetics
- Revise survival statistics in approximate ranges (do not memorise excessive numbers)
Cervix | |
Screening | NHCSP Cervical Cancer Screening 2020 |
SIP | #7 Progress in Cervical Screening in UK 2016 #21 Reproductive Outcomes after Local Treatment for Pre invasive Cervical Disease 2016 |
TOG | Cervical Cancer Elimination: what, how and WHO 2025 HPV-independent cervical cancer and its precursor lesions 2023 Cervical Cancer in Pregnancy: diagnosis, staging and treatment 2022 Cervical cancer prevention and screening: the role of HPV 2016 The management of Pregnancy after trachelectomy for early cervical cancer 2017 |
Endometrium | |
GTG | #67 Management of Endometrial Hyperplasia 2016 |
NICE | DG42 Testing Strategies for Lynch Syndrome with Endometrial cancer 2020 |
SIP | #32 Endometrial Cancer in Obese women #51 Sentinal lymph Node biopsy in Endometrial Cancer |
TOG | Detecting endometrial cancer 2021 Lynch Syndrome for gynecologist 2021 Unscheduled bleeding with HRT 2019 Endometrial Cancer and Obesity 2019 Endometrial pathology in the postmenopausal woman 2015 Management of women with postmenopausal bleeding 2012 |
Ovary | |
GTG | #34 The Management of Ovarian Cysts in Postmenopausal Women 2016 Minor Update Dec 2025 #62 Management of Suspected Ovarian Masses in Premenopausal Women 2011 |
NICE | CG122 Ovarian Cancer 2023 |
SIP | #52 Management of Female Malignant Ovarian Germ Cell Tumours 2016 #45 Management of Ascites in Ovarian Cancer Patients 2014 #44 The Distal Fallopian Tube as the Origin of Non-Uterine Pelvic High-Grade Serous Carcinomas (archived) #25 Optimum Surgery in Advanced-stage Ovarian Cancer 2011 #12 Targeted Therapies for the Management of Ovarian Cancer 2013 #66 Risk-Reducing Salpingo-oopherectomy and HRT below the Age of Natural Menopause 2021 #69 Use of Biomarkers to Stratify Surgical Care in Women with Ovarian Cancer 2022 |
TOG | Borderline Ovarian Tumours 2025 Endometriosis as a risk factor for ovarian cancer 2024 Hyperthermic intraperitoneal chemotherapy (HIPEC) in management of ovarian cancer 2024 Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer 2023 Non-epithelial Ovarian Cancers 2021 Raised CA125 2021 Management of ovarian cysts in children and adolescents 2020 Diagnosing adnexal tumours before surgery 2015 Risk-reducing surgery for women at high risk of epithelial ovarian cancer 2014 |
Vulva | |
RCOG | Guidelines for the Diagnosis and Management of Vulval Carcinoma 2014 |
BASHH | UK National Guideline on the Management of Vulval Conditions |
TOG | Squamous vulval cancer–an update 2013 The management of vulval itching caused by benign vulval dermatoses 2017 |
OGRM | Skin diseases affecting the vulva 2014 |
General Oncology | |
SIP | #48 Management of Women with a Genetic Predisposition to Gynaecological Cancers (Archived to NICE DG42) #35 Fertility-Sparing Treatments in Gynaecological Cancers (Archived) |
TOG | Global inequalities in management of gynae cancer 2025 Sentinel lymph node mapping in modern management of gynae malignancy 2023 Paraneoplastic Syndrome associated with Gynae Malignancy 2022 Shared decision making in gynaecological oncology; a challenge in an ageing population 2021 Fertility on ice: an overview of fertility preservation for children and adolescents with cancer 2021 HRT following treatment of gynaecological malignancies 2019 Pelvic exenteration for recurrent gynaecological cancer after radiotherapy 2017 Management of Gynaecological Cancer in Pregnancy 2017 Update on radiotherapy in gynaecological malignancies 2017 Surgical management of bowel obstruction in gynaecological cancer 2017 Pregnancy following treatment for malignancy 2016 Reproductive Health in female survivors of childhood cancer 2016 Update on Chemotherapy in gynaecological cancers 2016 The fallopian tube as origin of non-uterine pelvic high-grade serous carcinoma 2016 The molecular and genetic basis of inherited cancer risk in gynaecology 2015 Relationship between infertility and cancer 2013 |
Websites | https://www.cancerresearchuk.org/about-cancer |
British Gynaecological Cancer Society Guidelines |
Vulval Cancer 2024 |
Cervical Cancer 2020 |
BGCS Ovarian, Tubal and Primary Peritoneal Cancer Guideline 2024 |
BGCS Uterine Cancer Guidelines 2021 |
BAGP/BGCS FIGO Staging System for Vulvar Cancer 2021 |
Sentinel Consensus Document for Vulval, Endometrial and Cervical Cancer BGCS |
BGCS & British Menopause Society Guideline – Management of menopausal symptoms following treatment of gynae cancer 2024 |
BMS/BGC/BSGE joint guidance on management of women with unscheduled bleeding on HRT 2024 |
BGCS / BAGP consensus for genetic testing in epithelial ovarian cancer in UK 2024 |
FIGO Staging |
FIGO Ovarian Cancer Staging 2016 |
FIGO Staging for Vulval Cancer 2021 |
FIGO Staging Carcinoma of Vulva, Cervix, Endometrium and Sarcoma 2024 |

